Insider Buying: Lipocine (NASDAQ:LPCN) Director Purchases 12,561 Shares of Company Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 12,561 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was acquired at an average cost of $2.16 per share, for a total transaction of $27,131.76. Following the completion of the purchase, the director directly owned 216,358 shares in the company, valued at $467,333.28. This trade represents a 6.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lipocine Trading Up 1.9%

NASDAQ LPCN traded up $0.04 during trading hours on Wednesday, hitting $2.20. 31,369 shares of the company’s stock were exchanged, compared to its average volume of 33,043. The stock has a 50-day simple moving average of $2.17 and a 200 day simple moving average of $2.77. Lipocine Inc. has a 1-year low of $1.81 and a 1-year high of $12.37. The firm has a market cap of $18.13 million, a price-to-earnings ratio of -1.23 and a beta of 0.47.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. On average, sell-side analysts anticipate that Lipocine Inc. will post -1.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on LPCN. HC Wainwright restated a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a report on Monday, September 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.00.

Institutional Trading of Lipocine

Several institutional investors and hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Lipocine in the first quarter valued at about $998,000. Stempoint Capital LP bought a new position in shares of Lipocine during the 1st quarter worth approximately $1,282,000. ADAR1 Capital Management LLC purchased a new position in shares of Lipocine in the 1st quarter worth approximately $185,000. Eversept Partners LP purchased a new position in shares of Lipocine in the 1st quarter worth approximately $2,357,000. Finally, Exome Asset Management LLC bought a new position in shares of Lipocine in the first quarter valued at approximately $486,000. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.